Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Take Action: Urge Lawmakers to Support the RISE Act

Oncology Practice Insider

The pandemic has severely impacted America’s research pipeline and caused laboratories to shut down, which in turn means that many students and research staff have lost their jobs and valuable research progress. In addition to annual funding for the National Institutes of Health (NIH), emergency supplemental funding is critical to ensure our biomedical research enterprise and clinical trials networks can recover from disruptions caused by COVID-19.

ASCO supports the Research Investment to Spark the Economy (RISE) Act, S. 289/H.R. 869, introduced by Senators Ed Markey (D-MA) and Thom Tillis (R-NC) in the Senate and Representatives Diana DeGette (D-CO-1) and Fred Upton (R-MI-6) in the House to authorize $25 billion in emergency supplemental funding to a number of agencies, including $10 billion to the NIH. Researchers and graduate students would be able to use the funding to complete work disrupted by COVID-19, replace certain lab equipment, reconfigure laboratories to safely resume research, and cover increased construction costs resulting from the disruption from COVID-19.

As Congress continues work on COVID-19 relief legislation, ask your lawmakers to support this important legislation!